Shares of Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) have received a consensus rating of “Buy” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $49.00.
A number of research firms recently issued reports on SLP. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. BTIG Research reduced their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Stephens started coverage on Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price objective on the stock. KeyCorp reduced their target price on Simulations Plus from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research note on Wednesday.
View Our Latest Analysis on SLP
Insider Activity at Simulations Plus
Institutional Trading of Simulations Plus
Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its position in Simulations Plus by 106.0% in the third quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock valued at $1,517,000 after buying an additional 24,371 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Simulations Plus by 2.6% in the 3rd quarter. Principal Financial Group Inc. now owns 87,273 shares of the technology company’s stock valued at $2,794,000 after acquiring an additional 2,226 shares during the period. Franklin Resources Inc. boosted its position in shares of Simulations Plus by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 10,797 shares of the technology company’s stock worth $342,000 after purchasing an additional 766 shares during the period. Barclays PLC increased its holdings in Simulations Plus by 390.6% in the 3rd quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock valued at $911,000 after purchasing an additional 22,669 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Simulations Plus by 4.4% in the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock valued at $14,367,000 after purchasing an additional 18,924 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.
Simulations Plus Stock Performance
SLP opened at $28.25 on Tuesday. The company has a fifty day moving average of $29.82 and a two-hundred day moving average of $33.72. The stock has a market capitalization of $567.60 million, a price-to-earnings ratio of 57.65 and a beta of 0.80. Simulations Plus has a fifty-two week low of $24.00 and a fifty-two week high of $51.22.
Simulations Plus (NASDAQ:SLP – Get Free Report) last released its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The company had revenue of $18.70 million during the quarter, compared to analysts’ expectations of $19.73 million. During the same quarter in the prior year, the firm posted $0.18 EPS. Simulations Plus’s quarterly revenue was up 19.9% compared to the same quarter last year. On average, equities research analysts forecast that Simulations Plus will post 1.1 earnings per share for the current year.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Further Reading
- Five stocks we like better than Simulations Plus
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Trading Stocks: RSI and Why it’s Useful
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What is the Hang Seng index?
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.